Comparative Pharmacology
Head-to-head clinical analysis: ACCRUFER versus FERROUS FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCRUFER versus FERROUS FUMARATE.
ACCRUFER vs FERROUS FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACCRUFER (ferric maltol) is an oral iron replacement therapy. Ferric iron is complexed with maltol, which enhances absorption. Once absorbed, iron is utilized for hemoglobin synthesis and erythropoiesis.
Iron is an essential component of hemoglobin, myoglobin, and various enzymes; ferrous fumarate provides elemental iron for erythropoiesis and oxygen transport.
170 mg (1 tablet) orally twice daily (340 mg total daily dose) for adults with iron deficiency anemia, taken on an empty stomach at least 1 hour before or 2 hours after meals.
Oral: 200 mg (equivalent to 65 mg elemental iron) three times daily. Adults: 325 mg (106 mg elemental iron) one to three times daily.
None Documented
None Documented
20 hours (prolonged in hepatic impairment)
5-7 hours for iron in serum after absorption; terminal half-life of storage iron (ferritin) is approximately 6 days; clinical context: follows first-order kinetics with iron recycling.
Renal 65% (as unchanged drug), fecal 35%
Primarily fecal (about 90%) as unabsorbed iron; minor renal excretion (<1%) via sloughed intestinal cells and bile; negligible urinary elimination.
Category C
Category C
Iron Replacement
Iron Replacement